Literature DB >> 15681412

Antibody neutralization escape mediated by point mutations in the intracytoplasmic tail of human immunodeficiency virus type 1 gp41.

Vandana Kalia1, Surojit Sarkar, Phalguni Gupta, Ronald C Montelaro.   

Abstract

The persistence of human immunodeficiency virus type 1 (HIV-1) infection in the presence of robust host immunity has been associated in part with variation in viral envelope proteins leading to antigenic variation and escape from neutralizing antibodies. Previous studies of natural neutralization escape mutants have predominantly focused on gp120 and gp41 ectodomain sequence variations that alter antibody binding via changes in conformation or glycosylation pattern of the Env, likely due to the immune pressure exerted on the exposed ectodomain component of the glycoprotein. Here, we show for the first time a novel mechanism by which point mutations in the intracytoplasmic tail of the transmembrane component (gp41) of envelope can render the virus resistant to neutralization by monoclonal antibodies and broadly neutralizing polyclonal serum antibodies. Point mutations in a highly conserved structural motif within the intracytoplasmic tail resulted in decreased binding of neutralizing antibodies to the Env ectodomain, evidently due to allosteric changes both in the gp41 ectodomain and in gp120. While receptor binding and infectivity of the mutant virus remained unaltered, the changes in Env antigenicity were associated with an increase in neutralization resistance of the mutant virus. These studies demonstrate the structurally integrated nature of gp120 and gp41 and underscore a previously unrecognized potentially critical role for even minor sequence variation of the intracytoplasmic tail in modulating the antigenicity of the ectodomain of HIV-1 envelope glycoprotein complex.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15681412      PMCID: PMC546547          DOI: 10.1128/JVI.79.4.2097-2107.2005

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  42 in total

Review 1.  Challenges and opportunities for development of an AIDS vaccine.

Authors:  G J Nabel
Journal:  Nature       Date:  2001-04-19       Impact factor: 49.962

Review 2.  Viral persistence: HIV's strategies of immune system evasion.

Authors:  Welkin E Johnson; Ronald C Desrosiers
Journal:  Annu Rev Med       Date:  2002       Impact factor: 13.739

3.  Truncation of the cytoplasmic domain induces exposure of conserved regions in the ectodomain of human immunodeficiency virus type 1 envelope protein.

Authors:  Terri G Edwards; Stéphanie Wyss; Jacqueline D Reeves; Susan Zolla-Pazner; James A Hoxie; Robert W Doms; Frédéric Baribaud
Journal:  J Virol       Date:  2002-03       Impact factor: 5.103

Review 4.  HIV-1 entry inhibitors in the side pocket.

Authors:  J G Sodroski
Journal:  Cell       Date:  1999-10-29       Impact factor: 41.582

5.  Mutagenic stabilization and/or disruption of a CD4-bound state reveals distinct conformations of the human immunodeficiency virus type 1 gp120 envelope glycoprotein.

Authors:  Shi-Hua Xiang; Peter D Kwong; Rishi Gupta; Carlo D Rizzuto; David J Casper; Richard Wyatt; Liping Wang; Wayne A Hendrickson; Michael L Doyle; Joseph Sodroski
Journal:  J Virol       Date:  2002-10       Impact factor: 5.103

Review 6.  Antibodies, viruses and vaccines.

Authors:  Dennis R Burton
Journal:  Nat Rev Immunol       Date:  2002-09       Impact factor: 53.106

7.  The intracytoplasmic domain of the Env transmembrane protein is a locus for attenuation of simian immunodeficiency virus SIVmac in rhesus macaques.

Authors:  B L Shacklett; C J Weber; K E Shaw; E M Keddie; M B Gardner; P Sonigo; P A Luciw
Journal:  J Virol       Date:  2000-07       Impact factor: 5.103

8.  Human immunodeficiency virus type 1 neutralization measured by flow cytometric quantitation of single-round infection of primary human T cells.

Authors:  John R Mascola; Mark K Louder; Christine Winter; Ranjani Prabhakara; Stephen C De Rosa; Daniel C Douek; Brenna J Hill; Dana Gabuzda; Mario Roederer
Journal:  J Virol       Date:  2002-05       Impact factor: 5.103

9.  Antigenic properties of the human immunodeficiency virus envelope during cell-cell fusion.

Authors:  C M Finnegan; W Berg; G K Lewis; A L DeVico
Journal:  J Virol       Date:  2001-11       Impact factor: 5.103

10.  Interactions of the cytoplasmic domains of human and simian retroviral transmembrane proteins with components of the clathrin adaptor complexes modulate intracellular and cell surface expression of envelope glycoproteins.

Authors:  C Berlioz-Torrent; B L Shacklett; L Erdtmann; L Delamarre; I Bouchaert; P Sonigo; M C Dokhelar; R Benarous
Journal:  J Virol       Date:  1999-02       Impact factor: 5.103

View more
  39 in total

1.  Identification of amino acid substitutions associated with neutralization phenotype in the human immunodeficiency virus type-1 subtype C gp120.

Authors:  Jennifer L Kirchherr; Jennifer Hamilton; Xiaozhi Lu; S Gnanakaran; Mark Muldoon; Marcus Daniels; Webster Kasongo; Victor Chalwe; Chanda Mulenga; Lawrence Mwananyanda; Rosemary M Musonda; Xing Yuan; David C Montefiori; Bette T Korber; Barton F Haynes; Feng Gao
Journal:  Virology       Date:  2010-10-30       Impact factor: 3.616

2.  Reduced Potency and Incomplete Neutralization of Broadly Neutralizing Antibodies against Cell-to-Cell Transmission of HIV-1 with Transmitted Founder Envs.

Authors:  Hongru Li; Chati Zony; Ping Chen; Benjamin K Chen
Journal:  J Virol       Date:  2017-04-13       Impact factor: 5.103

3.  Differential functional phenotypes of two primary HIV-1 strains resulting from homologous point mutations in the LLP domains of the envelope gp41 intracytoplasmic domain.

Authors:  Jason T Newman; Timothy J Sturgeon; Phalguni Gupta; Ronald C Montelaro
Journal:  Virology       Date:  2007-06-19       Impact factor: 3.616

4.  Membrane structure correlates to function of LLP2 on the cytoplasmic tail of HIV-1 gp41 protein.

Authors:  Alexander L Boscia; Kiyotaka Akabori; Zachary Benamram; Jonathan A Michel; Michael S Jablin; Jonathan D Steckbeck; Ronald C Montelaro; John F Nagle; Stephanie Tristram-Nagle
Journal:  Biophys J       Date:  2013-08-06       Impact factor: 4.033

Review 5.  Structures and mechanisms of viral membrane fusion proteins: multiple variations on a common theme.

Authors:  Judith M White; Sue E Delos; Matthew Brecher; Kathryn Schornberg
Journal:  Crit Rev Biochem Mol Biol       Date:  2008 May-Jun       Impact factor: 8.250

6.  Highly conserved structural properties of the C-terminal tail of HIV-1 gp41 protein despite substantial sequence variation among diverse clades: implications for functions in viral replication.

Authors:  Jonathan D Steckbeck; Jodi K Craigo; Christopher O Barnes; Ronald C Montelaro
Journal:  J Biol Chem       Date:  2011-06-09       Impact factor: 5.157

7.  HIV-1 Cell-Free and Cell-to-Cell Infections Are Differentially Regulated by Distinct Determinants in the Env gp41 Cytoplasmic Tail.

Authors:  Natasha D Durham; Benjamin K Chen
Journal:  J Virol       Date:  2015-07-01       Impact factor: 5.103

8.  Clustering and mobility of HIV-1 Env at viral assembly sites predict its propensity to induce cell-cell fusion.

Authors:  Nathan H Roy; Jany Chan; Marie Lambelé; Markus Thali
Journal:  J Virol       Date:  2013-05-01       Impact factor: 5.103

9.  The lipid membrane of HIV-1 stabilizes the viral envelope glycoproteins and modulates their sensitivity to antibody neutralization.

Authors:  Hamid Salimi; Jacklyn Johnson; Manuel G Flores; Michael S Zhang; Yunxia O'Malley; Jon C Houtman; Patrick M Schlievert; Hillel Haim
Journal:  J Biol Chem       Date:  2019-11-22       Impact factor: 5.157

10.  Matrix and envelope coevolution revealed in a patient monitored since primary infection with human immunodeficiency virus type 1.

Authors:  Elodie Beaumont; Daniela Vendrame; Bernard Verrier; Emmanuelle Roch; François Biron; Françis Barin; Fabrizio Mammano; Denys Brand
Journal:  J Virol       Date:  2009-07-22       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.